Bristol Myers Squibb has agreed to pay $13.1 billion for MyoKardia, a clinical stage biopharmaceutical company focused on developing treatments for heart disease, the companies said Monday, in a deal built by Goodwin Public M&A and Life Sciences teams led by Stuart Cable, Lisa Haddad, Mitchell Bloom, Mike Patrone and Maggie Wong, with assistance from Kirby Lewis, Sarah Bock, Robert Crawford, Stephanie Philbin, Daniel Karelitz, Michael Jones, Jennifer Fay, Natalie Martirossian, Jackie Klosek, Grace Wirth, Cecelia Lockner, Hayden Hutton, William Stanton, Andre Amorim, Nicole Spiteri and Sophie Duffy. Read the Law360 article here.
Related Professionals
- Stuart M. Cable
- Lisa R. Haddad
- Mitchell S. Bloom
- Michael R. Patrone
- Maggie L. Wong
- Kirby H. Lewis
- Sarah M. Bock
- Robert M. Crawford, Jr.
- Stephanie Philbin
- Daniel S. Karelitz
- Michael T. Jones
- Jennifer Merrigan Fay
- Natalie Martirossian
- Jacqueline Klosek
- Grace L. Wirth
- Cecelia Lockner
- William Stanton
- Andre Amorim
- Nicole Spiteri
- Sophie Duffy